Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/17/2021 | $7.00 → $9.00 | Outperform | SVB Leerink |
| 9/3/2021 | $7.00 | Mkt Perform → Outperform | SVB Leerink |
| 9/3/2021 | Market Perform → Outperform | SVB Leerink | |
| 9/2/2021 | Market Perform → Outperform | SVB Leerink |
Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as of July 3, 2025: Total number of shares outstanding: 92,183,523 ordinary shares 6,434 Preferred Shares 2016 7,581 Preferred Shares 2017 Total number of theoretical voting rights (1): Total number of exercisable voting rights (2): 92,962,943 92,944,368 (1) The total number of
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that members of its executive team will participate in the upcoming investor conferences, detailed below. H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference Dates: June 24, 2025 | Virtual Wolfe Research Virtual Biotech Day Dates: June 26, 2025 | Virtual About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell En
Preclinical data from IPH6501, Innate's proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), will be presented Preclinical in vivo models support enhanced antitumor efficacy for the combination of IPH6501 with R-CHOP, the standard of care in untreated DLBCL and FL patients IPH6501 is currently under investigation in a Phase 1/2 clinical study in relapsed and/or refractory (R/R) CD20+ B-cell non-Hodgkin lymphoma Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced the presentation of preclinical data f
6-K - Innate Pharma SA (0001598599) (Filer)
6-K - Innate Pharma SA (0001598599) (Filer)
6-K - Innate Pharma SA (0001598599) (Filer)
SVB Leerink reiterated coverage of Innate Pharma with a rating of Outperform and set a new price target of $9.00 from $7.00 previously
SVB Leerink upgraded Innate Pharma from Mkt Perform to Outperform and set a new price target of $7.00
SVB Leerink upgraded Innate Pharma from Market Perform to Outperform
Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors Two new members would join the board of Directors Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from
Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO and co-founder Hervé Brailly will support the transition Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vice President and General Manager, Europe
Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and is appointed Executive Vice President, President of US Operations and to the Executive Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that it has strengthened the Company's leadership and corporate governance with the appointment of two new Executive Board members. Arvind Sood, Executive Vice President (EVP), President of US Operations, Dr Sonia Quaratino, EVP, Ch
€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET® program in autoimmune indications First patient dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors. Presentations at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome; long term follow up data from TELLOMAK Phase 2 to be presented at ASCO Annual Meeting 2025 Cash position of €72.5 million1 as of March 31, 2025, excluding the €15 million received from Sanofi, with a cash horizon to mid 2026 Conference call to b
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2025. In addition, members of the executive management team will be meeting with investors in New York and Boston from May 13 to May 14, 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Office
FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma were presented at ASH 2024 The first patient was dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors IPH6501, Innate's proprietary ANKET® drug candidate, is being evaluated in a Phase 1/2 clinical trial in patients with B-cell non-Hodgkin's lymphoma Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announced up to $7.9m investment from IFLI to support IPH6501 developm
SC 13D/A - Innate Pharma SA (0001598599) (Subject)
SC 13D/A - Innate Pharma SA (0001598599) (Subject)
SC 13D - Innate Pharma SA (0001598599) (Subject)